LevitasBio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 54

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $11.8M

  • Investors
  • 5

LevitasBio General Information

Description

Developer of a single-cell imaging and profiling platform designed to purify cells and nuclei without any markers or modifications. The company's platform utilises a groundbreaking cellular research and analysis method that allows scientists to examine, analyse, and understand biological signatures without altering, stressing, or damaging cells, all while preserving the original samples, enabling the life sciences market and healthcare industry to gain a deeper and more accurate understanding of biological processes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 31057 Genstar Road
  • Suit 137
  • Hayward, CA 94544
  • United States
+1 (650)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Corporate Office
  • 31057 Genstar Road
  • Suit 137
  • Hayward, CA 94544
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LevitasBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 10-Apr-2024 $11.8M Completed Generating Revenue
5. Later Stage VC (Series C) 24-Oct-2022 Completed Generating Revenue
4. Debt - General 28-Jul-2021 Completed Generating Revenue
3. Early Stage VC (Series B) 13-Jan-2021 Completed Generating Revenue
2. Early Stage VC 08-Apr-2019 Cancelled Generating Revenue
1. Early Stage VC (Series A) 03-Aug-2017 $8M $8M Completed Generating Revenue
To view LevitasBio’s complete valuation and funding history, request access »

LevitasBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C-1
Series C
Series B-1
Series B 14,048,803 $0.000010 8% $1.43 $1.43 1x $1.38 15.68%
Series A 8,166,599 $0.000010 8% $0.98 $0.98 1x $0.98 8.8%
To view LevitasBio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

LevitasBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a single-cell imaging and profiling platform designed to purify cells and nuclei without any markers or mod
Discovery Tools (Healthcare)
Hayward, CA
54 As of 2024

Santa Clara, CA
 

Ann Arbor, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LevitasBio Competitors (26)

One of LevitasBio’s 26 competitors is Applied Cells, a Venture Capital-Backed company based in Santa Clara, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Applied Cells Venture Capital-Backed Santa Clara, CA
Akadeum Life Sciences Venture Capital-Backed Ann Arbor, MI
Personal Genome Diagnostics Formerly VC-backed Baltimore, MD
Enrich Biosystems Venture Capital-Backed Branford, CT
Standard BioTools Formerly VC-backed Boston, MA
You’re viewing 5 of 26 competitors. Get the full list »

LevitasBio Patents

LevitasBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026006640-A1 Particle separator system, materials, and methods of use Pending 26-Jun-2024
WO-2026006640-A9 Particle separator system, materials, and methods of use Pending 26-Jun-2024
AU-2024234162-A1 Particle separator system, materials, and methods of use Pending 13-Mar-2023
EP-4680394-A1 Particle separator system, materials, and methods of use Pending 13-Mar-2023
US-20250271339-A1 Particle separator system, materials, and methods of use Pending 13-Mar-2023 C12M47/04
To view LevitasBio’s complete patent history, request access »

LevitasBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LevitasBio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Novalis LifeSciences Venture Capital Minority
StartX (US) Accelerator/Incubator Minority
The Pay It Forward Company Venture Capital Minority
Wuhan Thalys Medical Technology Corporation Minority
Decheng Capital Venture Capital Minority
To view LevitasBio’s complete investors history, request access »

LevitasBio FAQs

  • When was LevitasBio founded?

    LevitasBio was founded in 2017.

  • Where is LevitasBio headquartered?

    LevitasBio is headquartered in Hayward, CA.

  • What is the size of LevitasBio?

    LevitasBio has 54 total employees.

  • What industry is LevitasBio in?

    LevitasBio’s primary industry is Discovery Tools (Healthcare).

  • Is LevitasBio a private or public company?

    LevitasBio is a Private company.

  • What is the current valuation of LevitasBio?

    The current valuation of LevitasBio is .

  • What is LevitasBio’s current revenue?

    The current revenue for LevitasBio is .

  • How much funding has LevitasBio raised over time?

    LevitasBio has raised $73.8M.

  • Who are LevitasBio’s investors?

    Novalis LifeSciences, StartX (US), The Pay It Forward Company, Wuhan Thalys Medical Technology, and Decheng Capital have invested in LevitasBio.

  • Who are LevitasBio’s competitors?

    Applied Cells, Akadeum Life Sciences, Personal Genome Diagnostics, Enrich Biosystems, and Standard BioTools are some of the 26 competitors of LevitasBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process